Key Takeaways IBRX stock jumped on updated QUILT-106 data showing durable complete responses in Waldenstrom NHL.The study pairs off-the-shelf CD19 CAR-NK cells with Roche's Rituxan in an outpatient regimen without chemo.Results show 100% disease control to 15 months so far, with enrollment and follow-up in QUILT-106 ongoing.Shares of ImmunityBio (IBRX) surged 39.8% on Friday and added a further 9.4% in after-hours trading after the company reported updated efficacy and safety data from its ongoing QUILT-106 ...